INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial

Anushka Naidoo, Kelly E Dooley, Kogieleum Naidoo, Nesri Padayatchi, Nonhlanhla Yende-Zuma, Rubeshan Perumal, Gillian Dorse, Resha Boodhram, Emmanuella Chinonso Osuala, Anushka Naidoo, Kelly E Dooley, Kogieleum Naidoo, Nesri Padayatchi, Nonhlanhla Yende-Zuma, Rubeshan Perumal, Gillian Dorse, Resha Boodhram, Emmanuella Chinonso Osuala

Abstract

Introduction: Cotreatment of HIV and tuberculosis (TB) reduces morbidity and mortality in coinfected patients. Availability of antiretroviral treatment (ART) drug options, including within drug classes, is important, particularly in high HIV/TB burden low and middle-income countries.

Methods and analysis: This is a phase 2b, open-label, non-comparative randomised controlled trial to assess the antiretroviral activity of a fixed-drug, single tablet, combination of bictegravir (BIC) 50 mg/emtricitabine (FTC) 200 mg/tenofovir alafenamide (TAF) 25 mg (Biktarvy). The primary objective is to determine the efficacy, safety and pharmacokinetics of two times per day, coformulated BIC 50 mg/FTC 200 mg/TAF 25 mg in HIV-positive ART-naïve patients with TB who are receiving a rifampicin-based treatment regimen and to characterise viral suppression rates at week 24 through to week 48 in the BIC/FTC/TAF arm. We will enrol 120 patients randomised in a 2:1 ratio to the intervention or control arm of the study. A non-comparative contemporaneous control arm in which participants receive a dolutegravir-based regimen (standard of care) will also be enrolled.

Ethics and dissemination: The University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC) and the South African Health Products Regulatory Authority (SAHPRA) have granted regulatory approval (trial reference numbers: BREC/00001300/2020 and SAHPRA 20200810). Trial results will be disseminated through conference presentations, peer-reviewed publications and the clinical trial registry.

Trial registration number: Clinicaltrials.gov; Trial registration number: NCT04734652; South African National Clinical Trials Register (SANCTR DOH-27-012021-6789).

Keywords: Clinical trials; HIV & AIDS; Tuberculosis.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. UNAIDS . Unaids data 2018. Geneva, Switzerland: Joint United Nations Program on HIV AIDS, 2018.
    1. WHO . Policy brief: updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. Geneva, Switzerland: World Health Organization, 2018.
    1. Dorward J, Lessells R, Drain PK, et al. . Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. Lancet HIV 2018;5:e400–4. 10.1016/S2352-3018(18)30093-6
    1. Acosta RK, Willkom M, Martin R, et al. . Resistance analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 treatment-naive patients through 48 weeks. Antimicrob Agents Chemother 2019;63. 10.1128/AAC.02533-18. [Epub ahead of print: 25 04 2019].
    1. Deeks ED. Bictegravir/Emtricitabine/Tenofovir Alafenamide: a review in HIV-1 infection. Drugs 2018;78:1817–28. 10.1007/s40265-018-1010-7
    1. Gallant JE, Thompson M, DeJesus E, et al. . Antiviral activity, safety, and pharmacokinetics of Bictegravir as 10-day monotherapy in HIV-1-infected adults. J Acquir Immune Defic Syndr 2017;75:61–6. 10.1097/QAI.0000000000001306
    1. Stellbrink H-J, Arribas JR, Stephens JL, et al. . Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV 2019;6:e364–72. 10.1016/S2352-3018(19)30080-3
    1. Wohl DA, Yazdanpanah Y, Baumgarten A, et al. . Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV 2019;6:e355–63. 10.1016/S2352-3018(19)30077-3
    1. WHO . Global tuberculosis report 2018. Geneva, Switzerland: World Health Organization, 2018.
    1. Abdool Karim SS, Naidoo K, Grobler A, et al. . Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362:697–706. 10.1056/NEJMoa0905848
    1. WHO . Treatment of tuberculosis guidelines. 4th edition. Geneva, Switzerland: World Health Organisation, 2010.
    1. Reitman ML, Chu X, Cai X, et al. . Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther 2011;89:234–42. 10.1038/clpt.2010.271
    1. Joseph Custodio M M, Collins S, Vu A. Pharmacokinetics of bictegravir administered administered twice daily in combination with rifampin. Program and abstracts of the 2018 Conference on Retroviruses and Opportunistic Infections, Boston, 2018.
    1. Sax PE, Pozniak A, Montes ML, et al. . Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet 2017;390:2073–82. 10.1016/S0140-6736(17)32340-1
    1. White KL, Osman N, Cuadra-Foy E, et al. . Long dissociation of bictegravir from HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2021;65:e02406–20. 10.1128/AAC.02406-20
    1. Gilead Sciences . Biktarvy 50 mg/200 mg/25 Mg film-coated tablets: EU summary of product characteristics, 2018. Available: [Accessed 3 Jun 2019].
    1. Gilead Sciences . Biktarvy® (bictegravir, emtricitabine, and tenofovir alafenamide): US prescribing information, 2018. Available: [Accessed 3 Jun 2019].
    1. Maddalena Cerrone OA, Neary M, Marzinke MA, et al. . Rifampin effect on tenofovir alafenamide (TAF) plasma/ intracellular pharmacokinetics. 25th CROI. Boston. 4–7 March 2018. oral Abstract 28LB. 2018.
    1. Gish RG, Leung NWY, Wright TL, et al. . Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002;46:1734–40. 10.1128/AAC.46.6.1734-1740.2002
    1. Rousseau FS, Kahn JO, Thompson M, et al. . Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother 2001;48:507–13. 10.1093/jac/48.4.507
    1. Valade E, Tréluyer J-M, Bouazza N, et al. . Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. Antimicrob Agents Chemother 2014;58:2256–61. 10.1128/AAC.02058-13
    1. Natukunda E, Gaur AH, Kosalaraksa P, et al. . Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial. Lancet Child Adolesc Health 2017;1:27–34. 10.1016/S2352-4642(17)30009-3
    1. Lelievre J-D, Lelievre J-D, Kalayjian R, et al. . Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3B trial. Lancet HIV 2018. 10.1016/S2352-3018(18)30296-0. [Epub ahead of print: 13 Dec 2018].
    1. Brooks KM, George JM, Pau AK, et al. . Cytokine-Mediated systemic adverse drug reactions in a drug-drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine. Clin Infect Dis 2018;67:193–201. 10.1093/cid/ciy082
    1. Dooley KE, Kaplan R, Mwelase N, et al. . Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, Noncomparative, open-label, randomized trial. Clin Infect Dis 2019;365. 10.1093/cid/ciz256
    1. Dooley KE, Sayre P, Borland J, et al. . Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 2013;62:21–7. 10.1097/QAI.0b013e318276cda9
    1. Gengiah TN, Botha JH, Yende-Zuma N, et al. . Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment. Antivir Ther 2015;20:297–306. 10.3851/IMP2877
    1. Grinsztejn B, De Castro N, Arnold V, et al. . Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis 2014;14:459–67. 10.1016/S1473-3099(14)70711-X

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe